(Q35875744)

10 August 2017

0 references

Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib (English)

1 reference

10 August 2017

Goldstein JL

1

1 reference

10 August 2017

Eisen GM

2

1 reference

10 August 2017

Agrawal N

3

1 reference

10 August 2017

Stenson WF

4

1 reference

10 August 2017

Kent JD

5

1 reference

10 August 2017

Verburg KM

6

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Alimentary Pharmacology & Therapeutics

10 August 2017

published in

1 reference

10 August 2017

volume

20

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

527-538

1 reference

Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Cyclooxygenase-2: a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Basic biology and clinical application of specific cyclooxygenase-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Valdecoxib does not impair platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

The COX-2 Selective Inhibitor, Valdecoxib, Does Not Impair Platelet Function in the Elderly: Results of a Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

GI events leading to death in association with celecoxib and rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02118.X

10.1111/J.1365-2036.2004.02118.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference